Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma

• Published in: Journal of clinical oncology Vol. 41; no. 16_suppl; p. 9563
• Main Authors: Pecora, Andrew L, Rapisuwon, Suthee, Chen, Kevin, Gardner, Kellie, Cramer, Gayle, Blair, Danielle, Avergas, Amy, Swanson, Nicole, Ahn, Jaeil, Atkins, Michael B.
• Format: Journal Article
• Language: English
• Published: American Society of Clinical Oncology 01.06.2023

9563Background: Nivolumab/ipilimumab (Nivo/Ipi) is a standard therapy in patients with unresectable stage III/IV melanoma, demonstrating an objective response rate (ORR) of 58% and 12-month progression free survival (PFS) rate of 49% [Wolchok J, NEJM 2017]. c-MET/VEGFR2 inhibition with cabozantinib...